1 completed, 1 enrolling by invitation. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Pigmentary Glaucoma: new trials by email Literature Review of Pigmentary Glaucoma trials Research Report on Pigmentary Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Bausch & Lomb Incorporated | 176 | 2007-03-01 | 2020-09-14 |
Glaucoma, Open-Angle (2) · Exfoliation Syndrome (1) · Glaucoma (1) · Low Tension Glaucoma (1) · Ocular Hypertension (1)
Eye Diseases (2) · Glaucoma (1) · Iris Diseases (1) · Ocular Hypertension (1) · Optic Nerve Diseases (1) · Uveal Diseases (1)
Insulin (1) · Latanoprost (1)
Bausch & Lomb Incorporated (1) · Stanford University (1)
United States (2)
Jeffrey L Goldberg, MD PhD (1) · Kenneth Harper (1)